CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 152 enrolled
Drug / intervention
Lanraplenib +5 moredrug
Likely dose
Lanraplenib 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03100942
NCT03100942Phase 2Completed
CompareCT.gov

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome

Gilead Sciences·interventional·Posted Apr 4, 2017·Updated Oct 23, 2020

In Brief

A Phase 2 clinical trial evaluating Lanraplenib, Filgotinib, and 4 other interventions for Sjogren's Syndrome. Completed, enrolled 152 participants across 53 sites in 4 countries.

Detailed Summary

The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSjogren's Syndrome
CountriesPoland, Spain, United Kingdom, United States
CollaboratorsLakefront Biotherapeutics NV, Ono Pharmaceutical Co., Ltd.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 4, 2017
Enrollment StartMay 1, 2017
Primary CompletionJan 10, 2019
Study CompletionOct 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.2 years ago

Interventions

Lanraplenibdrug

1 x 30 mg tablet administered orally once daily

Filgotinibdrug

1 x 200 mg tablet administered orally once daily

Tirabrutinibdrug

1 x 40 mg tablet administered orally once daily

Lanraplenib placebodrug

1 x tablet administered orally once daily

Filgotinib placebodrug

1 x tablet administered orally once daily

Tirabrutinib placebodrug

1 x tablet administered orally once daily